Nature Communications · 2020 · 67 citations · 33 references
PharmacyPharmaceuticsPharmacologyDrug DeliverySignal TransductionTargeted Drug DeliveryAntibody ConjugatesAntibody-drug ConjugatesG Protein-coupled Receptor SignalingLigand BindingLigand-mediated TargetingTargeting LigandsBiological Activity FeaturesConjugationPeptide ConjugatesPeptide ConjugationPeptide-based ProbesPeptide-based TargetingPeptide-drug ConjugatesSignaling
Antibodies conjugated to bioactive compounds allow targeted delivery of therapeutics to cell types of choice based on that antibody's specificity. Here we develop a new type of conjugate that consists of a nanobody and a peptidic ligand for a G protein-coupled receptor (GPCR), fused via their C-termini. We address activation of parathyroid hormone receptor-1 (PTHR1) and improve the signaling activity and specificity of otherwise poorly active N-terminal peptide fragments of PTH by conjugating them to nanobodies (VHHs) that recognize PTHR1. These C-to-C conjugates show biological activity superior to that of the parent fragment peptide in vitro. In an exploratory experiment in mice, a VHH-PTH peptide conjugate showed biological activity, whereas the corresponding free peptide did not. The lead conjugate also possesses selectivity for PTHR1 superior to that of PTH(1-34). This design approach, dubbed "conjugation of ligands and antibodies for membrane proteins" (CLAMP), can yield ligands with high potency and specificity.
33
Blaine N. Armbruster, Xiang Li, Mark H. Pausch et al. · Proceedings of the National Academy of Sciences · 2007 · 2.1K citations · Full text
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
Jonathan T. Sockolosky, Eleonora Trotta, Giulia Parisi et al. · Science · 2018 · 373 citations · Full text